Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

This trial is testing whether adding venetoclax — a targeted drug that blocks a cancer cell survival protein — to a chemotherapy combination called CLAG-M can improve outcomes for people with acute myeloid leukemia (AML) or other high-grade blood cancers involving abnormal myeloid cells. The study covers both newly diagnosed high-risk patients and those whose disease has relapsed or is treatment-resistant. **You may be eligible if...** - You have a diagnosis of acute myeloid leukemia (AML) or a high-grade myeloid blood cancer (with 10% or more abnormal myeloid cells in blood or marrow) - For newly diagnosed: your disease is classified as high-risk (adverse risk AML) - For relapsed/refractory disease: your AML has come back or stopped responding to prior treatment - Mixed phenotype or biphenotypic acute leukemia is also eligible **You may NOT be eligible if...** - Your disease does not meet the required diagnostic criteria - Your overall health does not allow for intensive chemotherapy - You have had specific prior treatments that exclude you from this study Talk to your doctor to see if this trial is right for you.